UA95945C2 - Способ лечения рака предстательной железы, который включает проведение терапии депривацией андрогенов в комбинации с введением imc-а12 - Google Patents

Способ лечения рака предстательной железы, который включает проведение терапии депривацией андрогенов в комбинации с введением imc-а12

Info

Publication number
UA95945C2
UA95945C2 UAA200810850A UAA200810850A UA95945C2 UA 95945 C2 UA95945 C2 UA 95945C2 UA A200810850 A UAA200810850 A UA A200810850A UA A200810850 A UAA200810850 A UA A200810850A UA 95945 C2 UA95945 C2 UA 95945C2
Authority
UA
Ukraine
Prior art keywords
prostate cancer
androgen
deprivation therapy
cancer
androgen deprivation
Prior art date
Application number
UAA200810850A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Дейл Людвиг
Стефен Р. Плаймейт
Original Assignee
Имклоун Ллк
Юниверсити Оф Вашингтон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имклоун Ллк, Юниверсити Оф Вашингтон filed Critical Имклоун Ллк
Publication of UA95945C2 publication Critical patent/UA95945C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
UAA200810850A 2006-02-03 2007-02-03 Способ лечения рака предстательной железы, который включает проведение терапии депривацией андрогенов в комбинации с введением imc-а12 UA95945C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76507206P 2006-02-03 2006-02-03

Publications (1)

Publication Number Publication Date
UA95945C2 true UA95945C2 (ru) 2011-09-26

Family

ID=38345750

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200810850A UA95945C2 (ru) 2006-02-03 2007-02-03 Способ лечения рака предстательной железы, который включает проведение терапии депривацией андрогенов в комбинации с введением imc-а12

Country Status (17)

Country Link
US (1) US7972600B2 (enExample)
EP (1) EP1984011A4 (enExample)
JP (1) JP5198289B2 (enExample)
KR (1) KR101353706B1 (enExample)
CN (1) CN101484587B (enExample)
AP (1) AP2008004569A0 (enExample)
AU (1) AU2007212447B2 (enExample)
CA (1) CA2641310C (enExample)
CR (1) CR10188A (enExample)
EA (1) EA017265B1 (enExample)
EC (1) ECSP088706A (enExample)
IL (1) IL193203A0 (enExample)
MX (1) MX2008009977A (enExample)
NO (1) NO20083444L (enExample)
UA (1) UA95945C2 (enExample)
WO (1) WO2007092453A2 (enExample)
ZA (1) ZA200807012B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2860721B1 (en) 2007-02-01 2021-09-01 Dolby Laboratories Licensing Corporation Calibration of displays having spatially-variable backlight
RU2010119922A (ru) * 2007-10-19 2011-11-27 Фарма Мар, С.А. (Es) Усовершенствованное противоопухолевое лечение
US9084770B2 (en) * 2008-10-14 2015-07-21 Antisense Therapeutics, Ltd. Modulation of insulin like growth factor I receptor expression in cancer
SI2376116T1 (sl) 2008-12-12 2016-03-31 Boehringer Ingelheim International Gmbh Anti-IGF protitelesa
US20100214282A1 (en) 2009-02-24 2010-08-26 Dolby Laboratories Licensing Corporation Apparatus for providing light source modulation in dual modulator displays
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
WO2011057064A1 (en) * 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
KR101426134B1 (ko) * 2011-09-26 2014-08-06 한화케미칼 주식회사 항 ｉｇｆ-1ｒ 단일클론 항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
US9532972B2 (en) * 2012-02-07 2017-01-03 University Of Central Florida Research Foundation, Inc. Increasing taxane sensitivity in cancer cells
WO2014137946A1 (en) * 2013-03-04 2014-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of inhibiting igf-1r activation or downtream signalling thereof to reduce radiation-induced cellular senescence
US20140255413A1 (en) * 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
JP6346944B2 (ja) * 2013-09-19 2018-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組み合わせ薬物療法
CA2977000A1 (en) * 2015-03-16 2016-09-22 Ventana Medical Systems, Inc. Materials and methods for detecting androgen receptor splice variants and uses thereof
WO2021113794A1 (en) * 2019-12-06 2021-06-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Clinical decision support for personalized adaptive prostate cancer therapy
CN113512116B (zh) 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
TW202434307A (zh) 2023-01-18 2024-09-01 大陸商泰勵生物科技（上海）有限公司 抗體偶聯藥物及其用途

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
US4774321A (en) 1986-12-01 1988-09-27 Massachusetts Institute Of Technology DP100 EGF and insulin-binding protein from Drosophila cells
EP0308500B1 (en) 1987-04-06 1993-06-16 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
US5200509A (en) 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
CA2090703A1 (en) 1990-08-28 1992-03-01 Michael C. Kiefer Insulin-like growth factor binding protein (igfbp-4)
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5262308A (en) 1992-01-28 1993-11-16 Thomas Jefferson University Cell lines which constitutively express IGF-1 and IGF-1 R
US5597563A (en) 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
WO1994023034A2 (en) 1993-04-06 1994-10-13 Cedars-Sinai Medical Center Variant insulin-like growth factor i receptor subunits and methods for use thereof
AU1518595A (en) 1994-01-14 1995-08-01 Genentech Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
WO1996000084A1 (en) 1994-06-24 1996-01-04 Torchilin Vladimir P Use of autoantibodies for tumor therapy and prophylaxis
US5939269A (en) 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
ES2332984T3 (es) 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
EP0861267A4 (en) 1995-11-14 2000-02-02 Univ Jefferson INDUCTION AND RESISTANCE TO TUMOR GROWTH BY MEANS OF SOLUBLE IGF-1
AUPN999096A0 (en) 1996-05-22 1996-06-13 Northstar Biologicals Pty Ltd Peptides, antibodies, vaccines & uses thereof
US5798266A (en) 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US6071891A (en) 1996-11-22 2000-06-06 Regents Of The University Of Minnesota Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
DK1011648T4 (da) * 1997-08-15 2005-10-24 Cephalon Inc Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
ATE269100T1 (de) 1998-10-05 2004-07-15 Pharmexa As Verfahren zur therapeutischen impfung
EP1006184A1 (en) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
US7329745B2 (en) 2000-06-13 2008-02-12 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7071160B2 (en) 2000-06-15 2006-07-04 Kyowa Hakko Kogyo Co., Ltd. Insulin-like growth factor-binding protein
US8153121B2 (en) 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
EP1401476A4 (en) 2001-03-14 2006-03-08 Genentech Inc IGF-ANTAGONISTS PEPTIDES
WO2002087618A1 (en) 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
SI1461359T1 (sl) 2002-01-18 2007-06-30 Pf Medicament Nova anti IGF-IR protitelesa in njihova uporaba
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
NZ540971A (en) 2003-02-13 2008-04-30 Pfizer Prod Inc Uses of anti-insulin-like growth factor I receptor antibodies
WO2004083248A1 (en) 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
EP1613658B1 (en) 2003-04-02 2012-03-14 F. Hoffmann-La Roche AG Antibodies against insulin-like growth factor i receptor and uses thereof
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
US20050079184A1 (en) 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
UA85058C2 (ru) 2003-08-13 2008-12-25 Пфайзер Продактс Инк. Модифицированное моноклональное антитело человека, которое специфически связывается с рецептором подобного к инсулину фактора роста i человека (igf-ir)
CA2540133A1 (en) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. Drugs for treating cancer
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US20050164970A1 (en) * 2003-12-22 2005-07-28 University Of Kansas Medical Center Method for treating prostate cancer using siRNA duplex for androgen receptor
EP1737493B1 (en) 2004-02-25 2011-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor -1 for inhibiting tumor cell growth
PL1735348T3 (pl) * 2004-03-19 2012-11-30 Imclone Llc Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu
MX2007000610A (es) 2004-07-16 2007-03-07 Pfizer Prod Inc Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina.
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
EP2283831A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomakers for pre-selection of patients for anti-IGF1R therapy
US20060134172A1 (en) 2004-12-21 2006-06-22 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
BRPI0608175A2 (pt) 2005-04-15 2009-11-10 Immunogen Inc método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides
WO2006138729A2 (en) * 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
WO2007000328A1 (en) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
US20070009970A1 (en) 2005-07-08 2007-01-11 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
NO345919B1 (no) 2005-08-26 2021-10-18 Roche Glycart Ag Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet
CA2633956C (en) 2005-12-13 2016-12-06 Olivia Raeber Binding proteins specific for insulin-like growth factors and uses thereof

Also Published As

Publication number Publication date
EA200870231A1 (ru) 2009-12-30
EP1984011A2 (en) 2008-10-29
US7972600B2 (en) 2011-07-05
JP2009525348A (ja) 2009-07-09
WO2007092453A2 (en) 2007-08-16
WO2007092453A3 (en) 2008-12-24
AP2008004569A0 (en) 2008-08-31
ZA200807012B (en) 2009-12-30
CN101484587A (zh) 2009-07-15
NO20083444L (no) 2008-10-31
ECSP088706A (es) 2008-10-31
MX2008009977A (es) 2009-02-27
EA017265B1 (ru) 2012-11-30
EP1984011A4 (en) 2010-08-18
CR10188A (es) 2008-11-18
CA2641310C (en) 2013-08-20
KR101353706B1 (ko) 2014-02-18
KR20080090566A (ko) 2008-10-08
CA2641310A1 (en) 2007-08-16
IL193203A0 (en) 2009-08-03
AU2007212447A1 (en) 2007-08-16
JP5198289B2 (ja) 2013-05-15
CN101484587B (zh) 2014-02-12
US20090175868A1 (en) 2009-07-09
AU2007212447B2 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
UA95945C2 (ru) Способ лечения рака предстательной железы, который включает проведение терапии депривацией андрогенов в комбинации с введением imc-а12
BG108214A (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
WO2009137543A3 (en) Methods for breast cancer screening and treatment
TW200621240A (en) Cancer treatments
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
IN2012DN01964A (enExample)
WO2005016234A3 (en) Compositions, methods, apparatuses, and systems for singlet oxygen delivery
WO2022031642A3 (en) Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
WO2005000212A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
WO2009016488A3 (en) Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
WO2008060899A3 (en) Breast cancer screening and treatment methods
GB2470873A (en) Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
WO2007011372A3 (en) Therapeutic and prognostic factor yy1 in human cancer
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
Polkinghorn et al. Improving outcomes in high-risk prostate cancer with radiotherapy
AU4338501A (en) Combination chemotherapy
Díez et al. Dosimetric analysis of urethral strictures following HDR 192Ir brachytherapy as monotherapy for intermediate-and high-risk prostate cancer
PH12022553029A1 (en) Treatments of prostate cancer with combinations of abiraterone acetate and niraparib
Koontz et al. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
EP2817340A1 (en) Her3 inhibitor for modulating radiosensitivity
WO2022192182A3 (en) USES OF GLUCOCORTICOID RECEPTOR (GR) ANTAGONIST, ANTIANDROGEN, AND AKT INHIBITOR/PI3K INHIBITOR/mTOR INHIBITOR COMBINATIONS
D’Angelillo et al. Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era